Dr Reddy's to acquire Slayback's eyedrop rights
The company has inked a licensing pact with the US-based drug firm to acquire rights in Brimonidine Tartrate Ophthalmic Solution 0.025%
image for illustrative purpose
Hyderabad: Dr Reddy's Laboratories (DRL) on Saturday said it has entered into a licensing agreement with US-based Slayback Pharma to acquire rights of a medication to relieve redness of the eyes.
The company has inked a licensing pact with the NewJersey-based drug firm to acquire rights in Brimonidine Tartrate Ophthalmic Solution 0.025 per cent, the Hyderabad-based firm said in a statement.
The company's product is equivalent to Lumify, an over-the-counter (OTC) eyedrop that can be used to relieve redness of the eye due to minor eye irritations.
The agreement also provides Dr Reddy's exclusive rights to the product outside the US.
Marc Kikuchi, CEO (North America Generics), Dr Reddy's, said: "We are pleased to license this important OTC ophthalmic product for the US market. This product complements Dr Reddy's growing OTC product portfolio in the eyecare category that includes the private label versions of Pataday."
Slayback Pharma is the first company to file an ANDA (An Abbreviated New Drug Application) for the private label equivalent for Lumify with the USFDA (US Food & Drug Administration). The ANDA is currently under USFDA review and covers Brimonidine Tartrate Ophthalmic Solution 0.025 per cent in 2.5 ml and 7.5 ml fill volumes.
Ajay Singh, CEO and Founder of Slayback, said: "Slayback is proud to develop this first-to-file ANDA for Lumify, a significant OTC product in the eye redness reliever category, that continues to highlight the R&D capability of the company."
